These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 17079855

  • 21. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
    [Abstract] [Full Text] [Related]

  • 22. [Primum non nocere...inhaled glucocorticosteroids in 2003].
    Lacronique J.
    Rev Pneumol Clin; 2003 Jun; 59(3):129-37. PubMed ID: 13130199
    [Abstract] [Full Text] [Related]

  • 23. Glucocorticoid-induced osteoporosis.
    Tamura Y, Okinaga H, Takami H.
    Biomed Pharmacother; 2004 Nov; 58(9):500-4. PubMed ID: 15511606
    [Abstract] [Full Text] [Related]

  • 24. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
    Eiken PA, Hansen M, Kristensen B, Langdahl BL, Abrahamsen B.
    Ugeskr Laeger; 2011 Feb 21; 173(8):577-81. PubMed ID: 21333258
    [Abstract] [Full Text] [Related]

  • 25. Safety of inhaled corticosteroids.
    Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K.
    Proc Am Thorac Soc; 2004 Feb 21; 1(3):171-5. PubMed ID: 16113431
    [Abstract] [Full Text] [Related]

  • 26. [Clinical features of fracture with glucocorticoid induced osteoporosis and rheumatoid arthritis].
    Nampei A, Hashimoto J.
    Clin Calcium; 2006 Nov 21; 16(11):1866-70. PubMed ID: 17079854
    [Abstract] [Full Text] [Related]

  • 27. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A, Baio G, Mazzaglia G, Merlino L, Corrao G.
    Pharmacoepidemiol Drug Saf; 2008 Mar 21; 17(3):260-9. PubMed ID: 18240162
    [Abstract] [Full Text] [Related]

  • 28. Epidemiology of glucocorticoid-induced osteoporosis.
    Civitelli R, Ziambaras K.
    J Endocrinol Invest; 2008 Jul 21; 31(7 Suppl):2-6. PubMed ID: 18791344
    [Abstract] [Full Text] [Related]

  • 29. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
    van Staa TP, Leufkens HG, Cooper C.
    Osteoporos Int; 2002 Oct 21; 13(10):777-87. PubMed ID: 12378366
    [Abstract] [Full Text] [Related]

  • 30. [Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis].
    Tanaka I, Oshima H.
    Clin Calcium; 2007 Nov 21; 17(11):1738-44. PubMed ID: 17982195
    [Abstract] [Full Text] [Related]

  • 31. Chronic glucocorticoid therapy and osteoporosis--an under-recognised problem in South Africa.
    Pettifor JM.
    S Afr Med J; 2000 Nov 21; 90(11):1111-2. PubMed ID: 11196029
    [No Abstract] [Full Text] [Related]

  • 32. [Secondary osteoporosis. Glucocorticoid-induced osteoporosis: Threshold of bone mineral density for vertebral fracture].
    Soen S.
    Clin Calcium; 2007 Mar 21; 17(3):399-402. PubMed ID: 17339745
    [Abstract] [Full Text] [Related]

  • 33. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y.
    Clin Calcium; 2009 Jan 21; 19(1):85-90. PubMed ID: 19122268
    [Abstract] [Full Text] [Related]

  • 34. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P, Hamdy NA, Zwinderman AH, Ballieux BE, Papapoulos SE.
    Bone; 2009 May 21; 44(5):766-71. PubMed ID: 19442613
    [Abstract] [Full Text] [Related]

  • 35. [Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment].
    Bartl R.
    Dtsch Med Wochenschr; 2007 Jul 29; 132(27):1475-9. PubMed ID: 17583832
    [Abstract] [Full Text] [Related]

  • 36. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
    Perreault S, Dragomir A, Blais L, Moride Y, Rossignol M, Ste-Marie LG, Fernandès JC.
    Pharmacoepidemiol Drug Saf; 2008 Mar 29; 17(3):248-59. PubMed ID: 18213734
    [Abstract] [Full Text] [Related]

  • 37. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov 29; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 38. An overview of the adverse reactions to adrenal corticosteroids.
    Frauman AG.
    Adverse Drug React Toxicol Rev; 1996 Nov 29; 15(4):203-6. PubMed ID: 9113247
    [Abstract] [Full Text] [Related]

  • 39. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S.
    Clin Calcium; 2009 Jan 29; 19(1):44-53. PubMed ID: 19122264
    [Abstract] [Full Text] [Related]

  • 40. [Glucocorticoid-induced osteoporosis treatment algorithm].
    Payer J, Killinger Z, Brázdilová K.
    Vnitr Lek; 2009 May 29; 55(5):506-11. PubMed ID: 19514617
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.